The Middle East and Africa biomarker-based immunoassays market size was estimated at USD 165.4 million in 2024 and is projected to reach USD 234.2 million by 2033, growing at a CAGR of 3.8% from 2025 to 2033. The market growth is fueled by the rising global burden of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions, which require precise and early diagnostic tools. Increasing demand for personalized medicine has driven clinicians and pharmaceutical companies to adopt biomarker-guided strategies, where immunoassays play a central role in both disease detection and therapeutic monitoring. Countries like Saudi Arabia, the UAE, and South Africa are at the forefront, investing heavily in diagnostic infrastructure and adopting international best practices.
A key trend shaping the market is the growing collaboration between global diagnostic leaders and regional healthcare providers. For instance, in January 2025, Diatech Pharmacogenetics expanded its collaboration with Merck to extend access to RAS biomarker testing for colorectal cancer patients in MEA, underscoring the region’s rising focus on personalized cancer care. Such partnerships not only expand the availability of advanced biomarker assays but also accelerate technology transfer and capacity building across the region. This trend indicates that international companies view MEA as a critical growth frontier for precision diagnostics.
The MEA region offers untapped potential for biomarker-based immunoassays due to its expanding healthcare infrastructure and growing demand for precision medicine. Governments across Saudi Arabia, the UAE, and South Africa are investing heavily in advanced diagnostics to reduce dependence on overseas testing, which creates a strong opening for localized manufacturing and technology transfer. In addition, the rising prevalence of lifestyle-related diseases, combined with an increasing focus on early detection and personalized treatment, is driving adoption of biomarker assays in oncology, cardiology, and neurology. The growing emphasis on value-based care also positions biomarker testing as a cost-efficient solution, supporting earlier interventions and better patient outcomes.
Strategic collaborations are playing a critical role in shaping the MEA biomarker ecosystem. In 2025, Diatech Pharmacogenetics expanded its partnership with Merck to improve colorectal cancer care in the region through RAS biomarker testing, highlighting the momentum in companion diagnostics. Similarly, partnerships between diagnostic technology providers like IBL International and Grifols are advancing biomarker panels that could see uptake in MEA’s expanding clinical research networks. Meanwhile, local institutions, such as King Faisal Specialist Hospital in Saudi Arabia, are launching advanced biomarker testing programs that integrate with global standards, underscoring the region’s commitment to becoming a hub for innovation in precision diagnostics.
This product will be delivered within 2 business days.
A key trend shaping the market is the growing collaboration between global diagnostic leaders and regional healthcare providers. For instance, in January 2025, Diatech Pharmacogenetics expanded its collaboration with Merck to extend access to RAS biomarker testing for colorectal cancer patients in MEA, underscoring the region’s rising focus on personalized cancer care. Such partnerships not only expand the availability of advanced biomarker assays but also accelerate technology transfer and capacity building across the region. This trend indicates that international companies view MEA as a critical growth frontier for precision diagnostics.
The MEA region offers untapped potential for biomarker-based immunoassays due to its expanding healthcare infrastructure and growing demand for precision medicine. Governments across Saudi Arabia, the UAE, and South Africa are investing heavily in advanced diagnostics to reduce dependence on overseas testing, which creates a strong opening for localized manufacturing and technology transfer. In addition, the rising prevalence of lifestyle-related diseases, combined with an increasing focus on early detection and personalized treatment, is driving adoption of biomarker assays in oncology, cardiology, and neurology. The growing emphasis on value-based care also positions biomarker testing as a cost-efficient solution, supporting earlier interventions and better patient outcomes.
Strategic collaborations are playing a critical role in shaping the MEA biomarker ecosystem. In 2025, Diatech Pharmacogenetics expanded its partnership with Merck to improve colorectal cancer care in the region through RAS biomarker testing, highlighting the momentum in companion diagnostics. Similarly, partnerships between diagnostic technology providers like IBL International and Grifols are advancing biomarker panels that could see uptake in MEA’s expanding clinical research networks. Meanwhile, local institutions, such as King Faisal Specialist Hospital in Saudi Arabia, are launching advanced biomarker testing programs that integrate with global standards, underscoring the region’s commitment to becoming a hub for innovation in precision diagnostics.
MEA Biomarker-based Immunoassays Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. The analyst has segmented the Middle East & Africa biomarker-based immunoassays market report based on the sample, product, biomarkers, diseases, end-use, and country.Sample Outlook (Revenue, USD Million, 2021-2033)
- Blood
- Tissue
- Urine
- Saliva
Product Outlook (Revenue, USD Million, 2021-2033)
- Consumables
- Instruments/Analyzers
- Reagent & Kits
- Services
Biomarker Outlook (Revenue, USD Million, 2021-2033)
- Safety & toxicity biomarkers
- Efficacy & Pharmacodynamic Biomarkers
- Predictive & Prognostic Biomarkers
- Surrogate/Exploratory Biomarkers
Diseases Outlook (Revenue, USD Million, 2021-2033)
- Cancer
- Cardiovascular Diseases
- Neurological Diseases
- Immunological Diseases
- Others
End-use Outlook (Revenue, USD Million, 2021-2033)
- Hospitals & Clinics
- Diagnostic Laboratories
- Research & Academic Institutes
- Others
Regional Outlook (Revenue, USD Million, 2021-2033)
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the industry across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segmental and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. MEA Biomarker-Based Immunoassays Market Variables, Trends & Scope
Chapter 4. MEA Biomarker-Based Immunoassays Market: Sample Estimates & Trend Analysis
Chapter 5. MEA Biomarker-Based Immunoassays Market: Product Estimates & Trend Analysis
Chapter 6. MEA Biomarker-Based Immunoassays Market: Biomarker Estimates & Trend Analysis
Chapter 7. MEA Biomarker-Based Immunoassays Market: Diseases Estimates & Trend Analysis
Chapter 8. MEA Biomarker-Based Immunoassays Market: End-use Estimates & Trend Analysis
Chapter 9. MEA Biomarker-Based Immunoassays Market: Regional Estimates & Trend Analysis
Chapter 10. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The major companies profiled in this Middle East & Africa Biomarker-based Immunoassays market report include:- F. Hoffmann-La Roche AG
- Abbott
- Thermo Fisher Scientific Inc
- Erofins Scientific
- QIAGEN
- Bio-Rad Laboratories, Inc.
- Siemens Healthineers AG
- Merck KGaA
- PerkinElmer Inc.
- Agilent Technologies, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | August 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 165.4 Million |
| Forecasted Market Value ( USD | $ 234.2 Million |
| Compound Annual Growth Rate | 3.8% |
| Regions Covered | Africa, Middle East |
| No. of Companies Mentioned | 10 |
